JP4781494B2 - 不完全結晶性カルシウムホスフェートの製造法及びその使用法 - Google Patents
不完全結晶性カルシウムホスフェートの製造法及びその使用法 Download PDFInfo
- Publication number
- JP4781494B2 JP4781494B2 JP51857598A JP51857598A JP4781494B2 JP 4781494 B2 JP4781494 B2 JP 4781494B2 JP 51857598 A JP51857598 A JP 51857598A JP 51857598 A JP51857598 A JP 51857598A JP 4781494 B2 JP4781494 B2 JP 4781494B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium phosphate
- pca
- bone
- composition
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 558
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 550
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 537
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 524
- 238000000034 method Methods 0.000 title claims abstract description 141
- 230000008569 process Effects 0.000 title abstract description 27
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 345
- 239000000463 material Substances 0.000 claims abstract description 341
- 239000007943 implant Substances 0.000 claims abstract description 159
- 238000006243 chemical reaction Methods 0.000 claims abstract description 158
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 87
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 81
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 80
- 230000007547 defect Effects 0.000 claims abstract description 58
- 230000000399 orthopedic effect Effects 0.000 claims abstract description 22
- 239000004568 cement Substances 0.000 claims abstract description 13
- 230000001009 osteoporotic effect Effects 0.000 claims abstract description 13
- 210000003781 tooth socket Anatomy 0.000 claims abstract description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 182
- 239000000203 mixture Substances 0.000 claims description 160
- 239000002245 particle Substances 0.000 claims description 89
- 239000000843 powder Substances 0.000 claims description 65
- 239000011575 calcium Substances 0.000 claims description 63
- 229910052586 apatite Inorganic materials 0.000 claims description 48
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 48
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 33
- 239000003462 bioceramic Substances 0.000 claims description 32
- 210000003205 muscle Anatomy 0.000 claims description 28
- 238000002441 X-ray diffraction Methods 0.000 claims description 26
- 229910052791 calcium Inorganic materials 0.000 claims description 26
- 235000001465 calcium Nutrition 0.000 claims description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 25
- 239000000835 fiber Substances 0.000 claims description 22
- 229910019142 PO4 Inorganic materials 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 239000010452 phosphate Substances 0.000 claims description 21
- 235000021317 phosphate Nutrition 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 20
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 18
- -1 monetite Chemical compound 0.000 claims description 17
- 238000001228 spectrum Methods 0.000 claims description 17
- 239000000919 ceramic Substances 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000011230 binding agent Substances 0.000 claims description 13
- 239000002639 bone cement Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 12
- 210000002805 bone matrix Anatomy 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 11
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 10
- 230000036571 hydration Effects 0.000 claims description 10
- 238000006703 hydration reaction Methods 0.000 claims description 10
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 9
- 229920002643 polyglutamic acid Polymers 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 8
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 8
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 8
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 6
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 239000005313 bioactive glass Substances 0.000 claims description 6
- ROPDWRCJTIRLTR-UHFFFAOYSA-L calcium metaphosphate Chemical compound [Ca+2].[O-]P(=O)=O.[O-]P(=O)=O ROPDWRCJTIRLTR-UHFFFAOYSA-L 0.000 claims description 6
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000004917 carbon fiber Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- KBQIPTXDQGPPIO-UHFFFAOYSA-K heptacalcium;phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O KBQIPTXDQGPPIO-UHFFFAOYSA-K 0.000 claims description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 6
- 229910044991 metal oxide Inorganic materials 0.000 claims description 6
- 150000004706 metal oxides Chemical class 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003104 tissue culture media Substances 0.000 claims description 6
- 229920002732 Polyanhydride Polymers 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 239000012867 bioactive agent Substances 0.000 claims description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 5
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 5
- 239000001639 calcium acetate Substances 0.000 claims description 5
- 235000011092 calcium acetate Nutrition 0.000 claims description 5
- 229960005147 calcium acetate Drugs 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 229910000392 octacalcium phosphate Inorganic materials 0.000 claims description 5
- 150000004760 silicates Chemical class 0.000 claims description 5
- 229920002545 silicone oil Polymers 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 210000001847 jaw Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 7
- 239000006174 pH buffer Substances 0.000 claims 4
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 3
- 239000006260 foam Substances 0.000 claims 3
- 239000004626 polylactic acid Substances 0.000 claims 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 claims 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 239000010445 mica Substances 0.000 claims 2
- 229910052618 mica group Inorganic materials 0.000 claims 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 abstract description 150
- 239000002131 composite material Substances 0.000 abstract description 100
- 239000000945 filler Substances 0.000 abstract description 26
- 239000000376 reactant Substances 0.000 abstract description 25
- 230000012010 growth Effects 0.000 abstract description 24
- 230000035876 healing Effects 0.000 abstract description 14
- 230000036760 body temperature Effects 0.000 abstract description 10
- 208000010392 Bone Fractures Diseases 0.000 abstract description 7
- 230000008467 tissue growth Effects 0.000 abstract description 3
- 210000001909 alveolar process Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000153 supplemental effect Effects 0.000 abstract 1
- 239000006072 paste Substances 0.000 description 122
- 241001465754 Metazoa Species 0.000 description 59
- 239000008188 pellet Substances 0.000 description 58
- 239000000523 sample Substances 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 41
- 239000007787 solid Substances 0.000 description 40
- 230000011164 ossification Effects 0.000 description 37
- 239000000243 solution Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 30
- 239000000126 substance Substances 0.000 description 27
- 238000002513 implantation Methods 0.000 description 26
- 238000001727 in vivo Methods 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000009472 formulation Methods 0.000 description 23
- 230000009257 reactivity Effects 0.000 description 22
- 238000001356 surgical procedure Methods 0.000 description 22
- 239000011159 matrix material Substances 0.000 description 21
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 239000012153 distilled water Substances 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 210000004872 soft tissue Anatomy 0.000 description 17
- 230000008468 bone growth Effects 0.000 description 16
- 230000001054 cortical effect Effects 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 238000000227 grinding Methods 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 description 15
- 235000010755 mineral Nutrition 0.000 description 15
- 239000011707 mineral Substances 0.000 description 15
- 210000005009 osteogenic cell Anatomy 0.000 description 15
- 230000009103 reabsorption Effects 0.000 description 15
- 206010017076 Fracture Diseases 0.000 description 14
- 239000000316 bone substitute Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 206010002091 Anaesthesia Diseases 0.000 description 13
- 230000037005 anaesthesia Effects 0.000 description 13
- 230000006835 compression Effects 0.000 description 13
- 238000007906 compression Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 210000004373 mandible Anatomy 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 210000000515 tooth Anatomy 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 208000006735 Periostitis Diseases 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 210000003460 periosteum Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 9
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 9
- 239000004053 dental implant Substances 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 9
- 210000002303 tibia Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 230000009102 absorption Effects 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- 230000010478 bone regeneration Effects 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000007711 solidification Methods 0.000 description 7
- 230000008023 solidification Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 239000002250 absorbent Substances 0.000 description 6
- 230000002745 absorbent Effects 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 229910010293 ceramic material Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 239000004570 mortar (masonry) Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 230000017423 tissue regeneration Effects 0.000 description 6
- 241000282465 Canis Species 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 210000002449 bone cell Anatomy 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000007596 consolidation process Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 229940065514 poly(lactide) Drugs 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 239000004134 Dicalcium diphosphate Substances 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940125717 barbiturate Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229920013641 bioerodible polymer Polymers 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 230000022159 cartilage development Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000002648 chondrogenic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 3
- 229960001690 etomidate Drugs 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000012713 reactive precursor Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000009331 sowing Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 2
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 208000018035 Dental disease Diseases 0.000 description 2
- 208000001695 Dry Socket Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000012042 active reagent Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 229940052223 basic fuchsin Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 238000012669 compression test Methods 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000010758 granulomatous inflammation Diseases 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- URYAFVKLYSEINW-UHFFFAOYSA-N Chlorfenethol Chemical compound C=1C=C(Cl)C=CC=1C(O)(C)C1=CC=C(Cl)C=C1 URYAFVKLYSEINW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- ORSVWFJAARXBHC-UHFFFAOYSA-N carbamic acid;phosphoric acid Chemical compound NC(O)=O.OP(O)(O)=O ORSVWFJAARXBHC-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013036 cure process Methods 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000004453 electron probe microanalysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001214 frontal sinus Anatomy 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009972 noncorrosive effect Effects 0.000 description 1
- 239000002667 nucleating agent Substances 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 230000000395 remineralizing effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VQNBUJAEBQLLKU-UHFFFAOYSA-H tricalcium;diphosphate;hydrate Chemical compound O.[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VQNBUJAEBQLLKU-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/729,344 | 1996-10-16 | ||
| US08/732,016 US6027742A (en) | 1995-05-19 | 1996-10-16 | Bioresorbable ceramic composites |
| US08/729,343 | 1996-10-16 | ||
| US08/729,344 US6117456A (en) | 1995-05-19 | 1996-10-16 | Methods and products related to the physical conversion of reactive amorphous calcium phosphate |
| US08/732,016 | 1996-10-16 | ||
| US08/729,343 US20020136696A1 (en) | 1995-05-19 | 1996-10-16 | Orthopedic and dental ceramic implants |
| PCT/US1997/018631 WO1998016268A2 (en) | 1996-10-16 | 1997-10-16 | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001502215A JP2001502215A (ja) | 2001-02-20 |
| JP2001502215A5 JP2001502215A5 (enExample) | 2005-08-11 |
| JP4781494B2 true JP4781494B2 (ja) | 2011-09-28 |
Family
ID=27419129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51857598A Expired - Lifetime JP4781494B2 (ja) | 1996-10-16 | 1997-10-16 | 不完全結晶性カルシウムホスフェートの製造法及びその使用法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0936929B1 (enExample) |
| JP (1) | JP4781494B2 (enExample) |
| AT (1) | ATE269720T1 (enExample) |
| AU (1) | AU742748B2 (enExample) |
| CA (1) | CA2270185C (enExample) |
| DE (1) | DE69729647T2 (enExample) |
| DK (1) | DK0936929T3 (enExample) |
| ES (1) | ES2227719T3 (enExample) |
| WO (1) | WO1998016268A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6554803B1 (en) | 1997-04-02 | 2003-04-29 | Arthur Ashman | Combination syringe and aspirator for bone regeneration material and method for using the syringe |
| IT1299563B1 (it) * | 1998-07-17 | 2000-03-16 | Giovanni Dolci | Uso odontostomatologico di materiali a base apatitica nanostrutturati |
| CA2350638C (en) | 1998-09-11 | 2009-11-24 | Gerhard Schmidmaier | Biologically active implants coated with a biodegradable polymer |
| ATE291386T1 (de) * | 1999-10-21 | 2005-04-15 | Arthur Ashman | Kombination von spritze und sauger für knochenregenerationsmaterial |
| JP4669932B2 (ja) * | 2000-05-02 | 2011-04-13 | 学校法人日本大学 | 生体材料用組成物及びその硬化体 |
| JP4726281B2 (ja) * | 2000-07-27 | 2011-07-20 | テルモ株式会社 | 体内注入可能な組成物 |
| CA2426406A1 (en) * | 2000-10-24 | 2002-05-02 | Sdgi Holdings, Inc. | Spinal fusion methods and devices |
| AU2002220069B2 (en) * | 2000-10-24 | 2005-12-15 | Warsaw Orthopedic, Inc. | Methods and instruments for treating pseudoarthrosis |
| JP2002226241A (ja) * | 2001-01-30 | 2002-08-14 | Mitsui Constr Co Ltd | 真空凍結乾燥によるコンクリート材料のリサイクル方法 |
| JP2002296205A (ja) * | 2001-03-29 | 2002-10-09 | Japan Tissue Engineering:Kk | 培養組織の元素組成分析方法、移植適性判定方法及び品質管理方法並びに、移植適性を有する培養組織の製造方法及び移植適性を有する培養組織 |
| US6730324B2 (en) | 2001-04-20 | 2004-05-04 | The University Of British Columbia | Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| JP4473576B2 (ja) | 2001-11-19 | 2010-06-02 | スキール テヒノロギー ゲーエムベーハー | 骨誘導性および骨伝導特性を有するデバイス |
| US6840961B2 (en) * | 2001-12-21 | 2005-01-11 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| JP4358741B2 (ja) | 2002-09-10 | 2009-11-04 | スキール テヒノロギー ゲーエムベーハー | 低酸素濃度下において骨誘導性タンパク質で被覆された金属インプラント |
| US7776594B2 (en) | 2002-10-10 | 2010-08-17 | Wright Medical Technology, Inc. | Bone marrow infusion chamber and method |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| GB0307011D0 (en) | 2003-03-27 | 2003-04-30 | Regentec Ltd | Porous matrix |
| US20050101964A1 (en) * | 2003-11-07 | 2005-05-12 | Calcitec, Inc. | Spinal fusion procedure using an injectable bone substitute |
| DE10357460A1 (de) * | 2003-12-04 | 2005-07-07 | Friedrich-Baur-Gmbh | Bioresorbierbares Material |
| US20050136764A1 (en) | 2003-12-18 | 2005-06-23 | Sherman Michael C. | Designed composite degradation for spinal implants |
| US7459018B2 (en) | 2005-04-08 | 2008-12-02 | Howmedica Leibinger Inc. | Injectable calcium phosphate cement |
| US7416602B2 (en) | 2005-04-08 | 2008-08-26 | Howmedica Leibinger, Inc. | Calcium phosphate cement |
| DE102005022176B4 (de) * | 2005-05-09 | 2009-06-25 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur Herstellung von bioresorbierbaren Verbundmaterialien und seine Verwendung als Implantatmaterial sowie bioresorbiebaren Verbundmaterialien |
| DE202007015205U1 (de) * | 2007-10-05 | 2008-02-28 | Epple, Matthias, Prof. Dr. | Implantat |
| WO2009087421A2 (en) * | 2008-01-09 | 2009-07-16 | Oswestry Tissue Bank Ltd | Bone repair composition and a method of making the same |
| AU2015215892B2 (en) * | 2008-04-15 | 2017-11-30 | Life Science Enterprises, Inc. | Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement |
| WO2009129316A2 (en) * | 2008-04-15 | 2009-10-22 | Etex Corporation | Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement |
| EP2358651A2 (en) | 2008-11-12 | 2011-08-24 | Engqvist, Håkan | Hydraulic cements, methods and products |
| WO2011058443A1 (en) * | 2009-11-13 | 2011-05-19 | Barralet Jake E | Method and device to induce collagen biomineralisation |
| CN105125323B (zh) | 2010-03-10 | 2017-04-12 | 奥斯-Q公司 | 用于修复组织缺损的植入体和方法 |
| WO2012062360A1 (en) | 2010-11-10 | 2012-05-18 | Stryker Trauma Gmbh | Polymeric bone foam composition and method |
| US9463046B2 (en) | 2011-08-22 | 2016-10-11 | Ossdsign Ab | Implants and methods for using such implants to fill holes in bone tissue |
| US8591645B2 (en) | 2011-09-09 | 2013-11-26 | Ossdsign Ab | Hydraulic cements with optimized grain size distribution, methods, articles and kits |
| US20130066327A1 (en) | 2011-09-09 | 2013-03-14 | Håkan Engqvist | Hydraulic cement compositions with low ph methods, articles and kits |
| DE102012108320A1 (de) * | 2012-09-07 | 2014-03-13 | Aap Biomaterials Gmbh | Knochenzement sowie unter Verwendung eines Knochenzements hergestellter Formkörper |
| HK1216085A1 (zh) | 2012-12-14 | 2016-10-14 | Ossdsign Ab | 形成水泥的组合物、三斜磷钙石水泥、植入物及用於矫正骨缺损的方法 |
| HK1217632A1 (zh) | 2013-02-12 | 2017-01-20 | Ossdsign Ab | 镶嵌型植人物、试剂盒和用於矫正骨缺损的方法 |
| CN106999214B (zh) | 2014-08-14 | 2020-03-13 | 奥斯设计公司 | 镶嵌式植入物及其制造方法、支撑结构和植入物 |
| KR101631387B1 (ko) * | 2014-11-27 | 2016-06-16 | 에스케이이노베이션 주식회사 | 2,3-부탄디올로부터 1,3-부타디엔 및 메틸에틸케톤을 제조하는 데 사용되는 무정형 칼슘 포스페이트 촉매 및 촉매 제조 방법 |
| JP2016209599A (ja) * | 2016-05-20 | 2016-12-15 | ライフ サイエンス エンタープライジズ インコーポレイテッド | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
| CN109663147B (zh) * | 2019-02-19 | 2022-07-05 | 邢叔星 | 一种附着磷酸三钙缓释抗生素的peek植骨体及其制备方法 |
| CN118806988B (zh) * | 2023-04-21 | 2025-09-23 | 浙江大学 | 一种仿生多级球状矿化胶原支架的制备方法及应用 |
| CN116836022B (zh) * | 2023-06-25 | 2025-09-12 | 中国地质大学（武汉） | 一种多功能矿物土壤调理剂及其制备方法 |
| CN117383529A (zh) * | 2023-09-12 | 2024-01-12 | 华南理工大学 | 一种降低无定形磷酸钙稳定性的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117409A (ja) * | 1984-07-02 | 1986-01-25 | Meishin Toryo Kk | 非晶質リン酸カルシウムの製法およびこれを主成分とする生体適応性組成物 |
| JPS62224356A (ja) * | 1986-03-26 | 1987-10-02 | 太平化学産業株式会社 | 生体硬組織補修材料およびその製造法 |
| JPH01166765A (ja) * | 1987-12-23 | 1989-06-30 | Kobe Steel Ltd | 代替骨およびその製造方法 |
| US4880610A (en) * | 1988-04-20 | 1989-11-14 | Norian Corporation | In situ calcium phosphate minerals--method and composition |
| US5037639A (en) * | 1989-05-24 | 1991-08-06 | American Dental Association Health Foundation | Methods and compositions for mineralizing calcified tissues |
| JP3748567B2 (ja) * | 1990-07-27 | 2006-02-22 | ノリアン コーポレイション | 水酸化リン灰石への前駆体としてのカルシウム及びホスフェート源の均質混合物 |
| JP3115642B2 (ja) * | 1991-06-07 | 2000-12-11 | 日揮株式会社 | 人工骨材 |
| EP0520690B1 (en) * | 1991-06-26 | 1995-11-02 | Nitta Gelatin Inc. | Calcium phosphate type hardening material for repairing living hard tissue |
| GB9215356D0 (en) * | 1992-07-20 | 1992-09-02 | Univ Reading The | Bone materials |
| EP0672117A4 (en) * | 1992-08-13 | 1996-06-12 | Univ Pennsylvania | MATRIX BASED ON A BIOACTIVE MATERIAL FOR THE SYNTHESIS -i (IN VITRO) OF BONE TISSUE. |
| US5525148A (en) * | 1993-09-24 | 1996-06-11 | American Dental Association Health Foundation | Self-setting calcium phosphate cements and methods for preparing and using them |
| US5676976A (en) * | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US5783217A (en) * | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
-
1997
- 1997-10-16 AT AT97945578T patent/ATE269720T1/de not_active IP Right Cessation
- 1997-10-16 DK DK97945578T patent/DK0936929T3/da active
- 1997-10-16 ES ES97945578T patent/ES2227719T3/es not_active Expired - Lifetime
- 1997-10-16 JP JP51857598A patent/JP4781494B2/ja not_active Expired - Lifetime
- 1997-10-16 DE DE69729647T patent/DE69729647T2/de not_active Expired - Lifetime
- 1997-10-16 EP EP97945578A patent/EP0936929B1/en not_active Expired - Lifetime
- 1997-10-16 AU AU46746/97A patent/AU742748B2/en not_active Ceased
- 1997-10-16 WO PCT/US1997/018631 patent/WO1998016268A2/en not_active Ceased
- 1997-10-16 CA CA002270185A patent/CA2270185C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2270185C (en) | 2009-01-06 |
| AU4674697A (en) | 1998-05-11 |
| JP2001502215A (ja) | 2001-02-20 |
| ATE269720T1 (de) | 2004-07-15 |
| EP0936929A2 (en) | 1999-08-25 |
| AU742748B2 (en) | 2002-01-10 |
| WO1998016268A3 (en) | 1998-07-30 |
| WO1998016268A2 (en) | 1998-04-23 |
| ES2227719T3 (es) | 2005-04-01 |
| DE69729647D1 (de) | 2004-07-29 |
| DK0936929T3 (da) | 2004-11-08 |
| EP0936929B1 (en) | 2004-06-23 |
| CA2270185A1 (en) | 1998-04-23 |
| DE69729647T2 (de) | 2005-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4781494B2 (ja) | 不完全結晶性カルシウムホスフェートの製造法及びその使用法 | |
| US6953594B2 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| US7517539B1 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| US6287341B1 (en) | Orthopedic and dental ceramic implants | |
| US6117456A (en) | Methods and products related to the physical conversion of reactive amorphous calcium phosphate | |
| US6331312B1 (en) | Bioresorbable ceramic composites | |
| Schmitz et al. | Reconstruction of bone using calcium phosphate bone cements: a critical review | |
| EP0941079B1 (en) | Bioceramic compositions | |
| Pietrzak et al. | Calcium sulfate bone void filler: a review and a look ahead | |
| Kao et al. | A review of bone substitutes | |
| Shindo et al. | Facial skeletal augmentation using hydroxyapatite cement | |
| JP5792633B2 (ja) | モネタイトと他の生物活性カルシウムの複合物及びシリコン化合物に基づく骨再生材料 | |
| US4917702A (en) | Bone replacement material on the basis of carbonate and alkali containing calciumphosphate apatites | |
| JP4260880B2 (ja) | 骨代用物質及びその製造方法 | |
| US5605713A (en) | Process for the preparation of calcium phosphate cements and its application as bio-materials | |
| JP5091188B2 (ja) | 骨誘導性タンパク質のためのリン酸カルシウム送達ビヒクル | |
| Verheggen et al. | Correction of skull defects using hydroxyapatite cement (HAC)–evidence derived from animal experiments and clinical experience | |
| US20030055512A1 (en) | Calcium based neutral and bioresorbable bone graft | |
| US7150879B1 (en) | Neutral self-setting calcium phosphate paste | |
| US20020136696A1 (en) | Orthopedic and dental ceramic implants | |
| WO2006034420A2 (en) | Multi-purpose bio-material composition | |
| EP2080528B1 (en) | Preparation for regeneration of postoperative and post-traumatic bone defects | |
| Weiss et al. | Calcium phosphate bone cements: a comprehensive review | |
| Daculsi et al. | The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering | |
| WO2006076426A2 (en) | Multi-purpose bio-material composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081215 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081215 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20081215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090331 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090331 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100608 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100716 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100909 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110607 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110706 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D14 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |